PE20110055A1 - Dronedarona para la prevencion de la fibrilacion auricular permanente - Google Patents
Dronedarona para la prevencion de la fibrilacion auricular permanenteInfo
- Publication number
- PE20110055A1 PE20110055A1 PE2010001117A PE2010001117A PE20110055A1 PE 20110055 A1 PE20110055 A1 PE 20110055A1 PE 2010001117 A PE2010001117 A PE 2010001117A PE 2010001117 A PE2010001117 A PE 2010001117A PE 20110055 A1 PE20110055 A1 PE 20110055A1
- Authority
- PE
- Peru
- Prior art keywords
- dronedarone
- atrial fibrillation
- prevention
- permanent atrial
- atrial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Furan Compounds (AREA)
Abstract
REFERIDA AL 2-n-BUTIL-3-[4-(3-DI-n-BUTILAMINOPROPOXI)BENZOIL]-5-METILSULFONAMIDOBENZOFURANO O DRONEDARONA, EL CUAL ES UN AGENTE BLOQUEANTE MULTICANAL SOBRE LOS CANALES DE CALCIO, POTASIO Y SODIO Y ES UTIL EN EL TRATAMIENTO DE PACIENTES CON HISTORIAL DE FIBRILACION AURICULAR O ALETEO AURICULAR
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6026308P | 2008-06-10 | 2008-06-10 | |
EP08290531A EP2133074A1 (en) | 2008-06-10 | 2008-06-10 | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110055A1 true PE20110055A1 (es) | 2011-02-11 |
Family
ID=39731657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2010001117A PE20110055A1 (es) | 2008-06-10 | 2009-06-08 | Dronedarona para la prevencion de la fibrilacion auricular permanente |
Country Status (24)
Country | Link |
---|---|
US (1) | US20110166220A1 (es) |
EP (2) | EP2133074A1 (es) |
JP (1) | JP2011522876A (es) |
KR (1) | KR20110026422A (es) |
CN (1) | CN102056603A (es) |
AR (1) | AR072069A1 (es) |
AU (1) | AU2009259009A1 (es) |
CA (1) | CA2727326A1 (es) |
CL (1) | CL2010001422A1 (es) |
CO (1) | CO6280479A2 (es) |
CR (1) | CR11829A (es) |
DO (1) | DOP2010000365A (es) |
EA (1) | EA201071378A1 (es) |
EC (1) | ECSP10010666A (es) |
IL (1) | IL209791A0 (es) |
MA (1) | MA32462B1 (es) |
MX (1) | MX2010013698A (es) |
NI (1) | NI201000211A (es) |
PE (1) | PE20110055A1 (es) |
SV (1) | SV2010003756A (es) |
TW (1) | TW201002676A (es) |
UY (1) | UY31886A (es) |
WO (1) | WO2009150535A1 (es) |
ZA (1) | ZA201008871B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102065855A (zh) | 2008-04-17 | 2011-05-18 | 赛诺菲-安万特 | 决奈达隆在制备用于预防因心血管疾病住院或死亡的药物中的用途 |
FR2930149B1 (fr) * | 2008-04-17 | 2011-02-18 | Sanofi Aventis | Association de dronedarone avec au moins un diuretique, son application en therapeutique |
EP2116239A1 (en) * | 2008-04-29 | 2009-11-11 | Sanofi-Aventis | Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment |
AU2014274638B2 (en) * | 2009-12-21 | 2016-09-15 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
TWI508726B (zh) * | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
WO2011141888A1 (en) * | 2010-05-13 | 2011-11-17 | Sanofi | Use of dronedarone for the preparation of a medicament for the prevention of cardiovacular hospitalizations or death or cardiovascular events in patients with permanent atrial fibrillation |
EP2387996A1 (en) * | 2010-05-17 | 2011-11-23 | Sanofi | Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation |
EP2387997A1 (en) * | 2010-05-18 | 2011-11-23 | Sanofi | Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients who developed permanent atrial fibrillation throughout the period the dronedarone is administered |
US8602215B2 (en) | 2010-06-30 | 2013-12-10 | Sanofi | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
WO2012020377A1 (en) * | 2010-08-11 | 2012-02-16 | Sanofi | Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation |
WO2012023024A2 (en) * | 2010-08-17 | 2012-02-23 | Lupin Limited | Controlled release formulations of dronedarone |
EP3326616B1 (en) * | 2011-06-03 | 2021-07-28 | Signpath Pharma Inc. | Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current |
EP2543363A1 (en) * | 2011-07-07 | 2013-01-09 | Sanofi | Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts |
EP2543362A1 (en) * | 2011-07-07 | 2013-01-09 | Sanofi | Sustained release pharmaceutical oral solid dosage form of dronedarone or one of its pharmaceutically acceptable salts |
EP2543361A1 (en) * | 2011-07-07 | 2013-01-09 | Sanofi | Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts |
FR2977495B1 (fr) * | 2011-07-07 | 2014-03-07 | Sanofi Sa | Composition pharmaceutique et forme galenique solide a haute teneur en dronedarone et son procede de preparation |
WO2013024411A1 (en) | 2011-08-12 | 2013-02-21 | Lupin Limited | Co-milled formulation of dronedarone |
CN112336445B (zh) * | 2019-12-26 | 2021-11-26 | 上海微创电生理医疗科技股份有限公司 | 一种消融系统及其神经探测设备 |
-
2008
- 2008-06-10 EP EP08290531A patent/EP2133074A1/en not_active Withdrawn
-
2009
- 2009-06-08 CA CA2727326A patent/CA2727326A1/en not_active Abandoned
- 2009-06-08 CN CN2009801219070A patent/CN102056603A/zh active Pending
- 2009-06-08 PE PE2010001117A patent/PE20110055A1/es not_active Application Discontinuation
- 2009-06-08 JP JP2011513071A patent/JP2011522876A/ja not_active Withdrawn
- 2009-06-08 WO PCT/IB2009/006106 patent/WO2009150535A1/en active Application Filing
- 2009-06-08 MX MX2010013698A patent/MX2010013698A/es not_active Application Discontinuation
- 2009-06-08 EA EA201071378A patent/EA201071378A1/ru unknown
- 2009-06-08 KR KR1020107027660A patent/KR20110026422A/ko not_active Application Discontinuation
- 2009-06-08 EP EP09762063A patent/EP2300001A1/en not_active Withdrawn
- 2009-06-08 AU AU2009259009A patent/AU2009259009A1/en not_active Abandoned
- 2009-06-08 AR ARP090102050A patent/AR072069A1/es unknown
- 2009-06-10 UY UY0001031886A patent/UY31886A/es not_active Application Discontinuation
- 2009-06-10 TW TW098119393A patent/TW201002676A/zh unknown
-
2010
- 2010-11-29 DO DO2010000365A patent/DOP2010000365A/es unknown
- 2010-12-06 NI NI201000211A patent/NI201000211A/es unknown
- 2010-12-06 IL IL209791A patent/IL209791A0/en unknown
- 2010-12-07 US US12/962,102 patent/US20110166220A1/en not_active Abandoned
- 2010-12-07 CR CR11829A patent/CR11829A/es not_active Application Discontinuation
- 2010-12-08 EC EC2010010666A patent/ECSP10010666A/es unknown
- 2010-12-09 CO CO10154617A patent/CO6280479A2/es not_active Application Discontinuation
- 2010-12-09 ZA ZA2010/08871A patent/ZA201008871B/en unknown
- 2010-12-09 SV SV2010003756A patent/SV2010003756A/es unknown
- 2010-12-10 CL CL2010001422A patent/CL2010001422A1/es unknown
-
2011
- 2011-01-07 MA MA33501A patent/MA32462B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009150535A1 (en) | 2009-12-17 |
AU2009259009A1 (en) | 2009-12-17 |
EP2300001A1 (en) | 2011-03-30 |
SV2010003756A (es) | 2011-03-15 |
UY31886A (es) | 2010-01-29 |
CR11829A (es) | 2011-01-11 |
JP2011522876A (ja) | 2011-08-04 |
IL209791A0 (en) | 2011-02-28 |
DOP2010000365A (es) | 2011-01-15 |
NI201000211A (es) | 2011-04-27 |
ZA201008871B (en) | 2012-02-29 |
EP2133074A1 (en) | 2009-12-16 |
ECSP10010666A (es) | 2011-01-31 |
CA2727326A1 (en) | 2009-12-17 |
CO6280479A2 (es) | 2011-05-20 |
CL2010001422A1 (es) | 2011-05-13 |
KR20110026422A (ko) | 2011-03-15 |
US20110166220A1 (en) | 2011-07-07 |
MA32462B1 (fr) | 2011-07-03 |
TW201002676A (en) | 2010-01-16 |
EA201071378A1 (ru) | 2011-06-30 |
WO2009150535A8 (en) | 2010-12-23 |
CN102056603A (zh) | 2011-05-11 |
AR072069A1 (es) | 2010-08-04 |
MX2010013698A (es) | 2011-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110055A1 (es) | Dronedarona para la prevencion de la fibrilacion auricular permanente | |
CL2016002589A1 (es) | Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
NO20091395L (no) | Nye tiofenderivater | |
CU23815A3 (es) | Diarilureas para el tratamiento de hipertensión pulmonar | |
CL2013003598A1 (es) | Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras | |
HN2008000278A (es) | Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion terapeutica | |
BRPI0811893A2 (pt) | Composição de borracha acrílica e borracha vulcanizada da mesma, e suas aplicações. | |
ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
WO2009026657A8 (en) | Flavonoid ppar agonists | |
NL1036050C (nl) | Brandvertragende en brandwerende samenstelling. | |
ATE510822T1 (de) | Kaliumkanalinhibitoren | |
ECSP10010471A (es) | Agonistas nicotínicos alfa 7 y antipsicóticos | |
HN2006015130A (es) | Asociacion entre la ferroquina y un derivado de artemisina para el tratamiento del paludismo | |
DOP2010000075A (es) | Compuesto inhibidor de glicógeno fosforilasa y composicion farmaceutica del mismo | |
MX2016007436A (es) | Composiciones para el cuidado oral que comprenden carbonato de calcio y talco. | |
CL2009000904A1 (es) | Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende. | |
CL2010001421A1 (es) | Uso de dronedarona en la preparacion de medicamentos utiles para la prevencion de fibrilacion o aleteo auricular persistentes. | |
BRPI0917554A2 (pt) | agente de tratamento ou agente de prevenção para oesteoartrite | |
TR201101807T2 (tr) | Rosuvastatin kalsiyumun farmasotik bileşimleri | |
ECSP10010552A (es) | Asociacion de LA dronedarona con al menos un diuretico, su aplicacion en terapeutica | |
BRPI0816810A2 (pt) | utilização de pelo menos um composto, e, composto. | |
GT200600408A (es) | Nueva asociacion entre agomelatina y un inhibidor de recaptura de noradrenalina y composiciones farmaceuticas que la contienen | |
FR2876036B3 (fr) | Structure de seringue hypodermique de surete. | |
CL2007001794A1 (es) | Compuestos derivados de 2-imidazolidinona, inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y su uso para tratar o prevenir arritmias cardiacas. tromboembolia,apoplejia,insuficiencia cardiaca. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |